tbuckley/cabot-search huggingface dataset:
1174P FLAMINGO: Accurate cancer detection from ultra-low-pass whole genome sequencing of cell-free DNA
Authors: D. Vessies, T. Bucho, E. Post, K. Roohollahi, J. van den Berg, A. Foster, S. Patel, A. Vandor, D. Makarawung, F. van Asch
Journal: Annals of Oncology (2024)
1053P The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based study
Authors: A.J. Alghabban, R. Sutradhar, V. Aghanya, Y. Kaliwal, Y. Niu, N. Liu, Y. Liu, M. Powis, G. Liu, J. Peppercorn, M.K. Krzyzanowska, L. Eng
Journal: Annals of Oncology (2024)
1093P Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma
Authors: P.A. Ascierto, M. Ziemer, J.C. Hassel, P. Rutkowski, F. Meier, L. Flatz, C. Gaudy Marqueste, M. Santinami, F. Russano, I. von Wasielewski, T.K. Eigentler, M. Maio, I. Zalaudek, S. Haferkamp, P. Quaglino, C. Garbe, K.C. Kähler, C. Robert, A. Hauschild, D. Schadendorf
Journal: Annals of Oncology (2024)
1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Authors: A.M.M. Eggermont, M. Kicinski, C.U. Blank, M. Mandalà, G.V. Long, V.G. Atkinson, S. Dalle, A.M. Haydon, A. Meshcheryakov, M.A. Khattak, M.S. Carlino, S.K. Sandhu, S. Puig Sarda, P.A. Ascierto, P. Lorigan, D. Grebennik, C. Krepler, S.I. Marreaud, S. Suciu, C. Robert
Journal: Annals of Oncology (2024)
1159P Molecular characterization of extra-pulmonary mixed adeno-neuroendocrine carcinomas: The NIRVANA substudy
Authors: F. Spada, E. Pisa, A. Ranghiero, S. Frassoni, V. Bagnardi, L. Gervaso, D. Tamayo, C. Mazzon, L. Benini, C.A. Cella, D. Ciardiello, N. Fazio
Journal: Annals of Oncology (2024)
1155P Updated results of surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomized, controlled trial
Authors: D. Cao, X. Li, X. You, R. Li, J. Xiang, H. Lan, J. Wang, N. Ke
Journal: Annals of Oncology (2024)
1112P Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Authors: D.C. Ziogas, G. Lyrarakis, M. Liontos, A. Anastasopoulou, S. Bouros, A. Gkoufa, P. Diamantopoulos, H. Gogas
Journal: Annals of Oncology (2024)
1069TiP A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies
Authors: M.R. Sharma, D. Rasco, S. Kummar, D. Maslyar, D. Strahs, D.M. Glatt, K. Gerrick
Journal: Annals of Oncology (2024)
1118P Immunological alterations during neoadjuvant BRAF/MEK inhibition in patients with prior unresectable regionally advanced melanoma: Translational analysis from the REDUCTOR trial
Authors: F. Burgers, M. Rohaan, T. Seijkens, S. Blankenstein, B. van de Wiel, J. Sanders, M. Klop, W. Van Houdt, A.C.J. van Akkooi, J.B.A.G. Haanen
Journal: Annals of Oncology (2024)
1010P Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Authors: J. Henry, S. Manda, X. Tao, K. Lin, F. Zheng, Y. Wei, F. Li, L. Rosenstein, W. Xu, B. Garmezy
Journal: Annals of Oncology (2024)
955P Association of skeletal muscle mass with safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the ELIXIR study
Authors: A. Hiraoka, H. Aikata, M. Moriguchi, M. Ikeda, N. Morimoto, K. Tsuchiya, T. Takehara, H. Nagai, R. Sakamori, S. Nakamura, K. Tsuji, H. Kuroda, M. Shimizu, S. Shiina, T. Yamasaki, M. Kudo, N. Kokudo, J. Furuse, K. Yamamoto, T. Yamashita
Journal: Annals of Oncology (2024)
949P Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
Authors: X. Mao, X. Duan, D. Wu, C. Zhou, Y. Tian, J. Shen, G. Xu, Y. Bai
Journal: Annals of Oncology (2024)
1017P Updated safety and efficacy from the phase I study of givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in claudin 18.2 positive advanced gastroesophageal carcinoma (GEC)
Authors: S.J. Klempner, L. Shen, D. Liu, F. Dayyani, J. Kratz, H. Pan, X. Liang, Z. Wang, S. Kim, Y. Deng, T. Deng, T. Liu, E. Girda, C. Xu, M.T. Nguyen, J. Xia, X. Wang, S. Lee, J. Jeon, G.Y. Ku
Journal: Annals of Oncology (2024)
1007P Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Authors: K.J. Harrington, S. Kitano, V. Gambardella, E.E. Parkes, I. Moreno Candilejo, G. Alonso Casal, T. Doi, D. Berz, M. Gutierrez, N. Fernandez, B. Li, J. Barrueco, P. Lorusso
Journal: Annals of Oncology (2024)
1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
Authors: S. Champiat, C. Lebbe, J-F. Baurain, A. Italiano, M. Sakkal, C. Spring-Giusti, N. Stojkowitz, M. Brandely, A. Sadoun, A. Ropenga, M. Semmrich, A. McAllister, M. Chisamore, P. Cassier
Journal: Annals of Oncology (2024)
972P Efficacy and safety of lenvatinib vs sorafenib in hepatocellular carcinoma: A multi-center real-world study from the LINK Research Network
Authors: J.Y. Hong, M. Kang, D.H. Sinn, W.C. Cha, W.K. Jeong, D-Y. Kim, M.J. Lee, S. Lim, D. Kim, K-P. Kim, B-Y. Ryoo, W-M. Choi, K. Kim, K-H. Kim, E.J. Choi, C. Jung, D. Lee, J. Kim
Journal: Annals of Oncology (2024)
965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW
Authors: T. Decaens, T. Yau, M. Kudo, B. Sangro, S. Qin, L. Da Fonseca, H. Karachiwala, J-W. Park, E. Gane, M. Pinter, D.W.M. Tai, A. Santoro, G. Pizarro, C-F. Chiu, M. Schenker, A.R. He, Q. Wang, T. Ogata, J. Hreiki, P.R. Galle
Journal: Annals of Oncology (2024)
969P Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational study
Authors: P. Lombardi, G.F. Manfredi, C. Celsa, B. Stefanini, T. Marron, A. Saeed, M. Pinter, S. Ulahannan, F. Piscaglia, C-Y. Lin, A. Dalbeni, G. Masi, M. Schoenlein, P.R. Galle, M. Kudo, L. Rimassa, H. Chon, M. Pirisi, D.J. Pinato
Journal: Annals of Oncology (2024)
962P Best practices and impact of multi-disciplinary teams on hepatocellular carcinoma treatment: Insights from a global effort
Authors: P. Azcue, M.T. Campos Partera, A. Vogel, G. Sapisochin, A. Digklia, G.E. Villadsen, C. Schnatwinkel, M. Kothari, M. Gallego-Llorente, Y.P. Cui, T. Flieswasser, L. Turner, W. Vereecken, A. Moucquot, H. Naqvi, D. Dellamonica
Journal: Annals of Oncology (2024)
999MO HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma
Authors: C.H.H. Ottensmeier, E. King, S. Crabb, I. Karydis, D.M. Graham, K. Martin, I. Eberhart, S. Ewings, P. Lee, K. McCann, L. Chudley, L. Berry, J. Dias, R. Das, J. Furlanetto, E. Johnson, J. Setzer, U. Sahin, Ö. Türeci, G. Griffiths
Journal: Annals of Oncology (2024)
985P Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC)
Authors: A.O. Kaseb, J. Bugni, M. Karkhanis, X. Meng, T. Wei, M. Zhou, K. Shen, C. Yang, M. Yu, S.H. Jang, K. Ryan, L. Alexander
Journal: Annals of Oncology (2024)
1088P Molecular profiling and matched targeted therapy for patients with advanced melanoma: Results from part I of the MatchMEL study
Authors: A. Boutros, M.S. Carlino, M. Gonzalez, S.N. Lo, A. Colebatch, R. Rawson, J. Wilmott, H. Rizos, R.A. Scolyer, I. Pires da Silva, G.V. Long, A.M. Menzies
Journal: Annals of Oncology (2024)
1204P Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Authors: H.L. Robbins, E. Leung, S. Zaman, N. Lal, D. Morton, L. Dew, A. Williams, Y. Wallis, J. Bell, M. Raghavan, G. Middleton, A.D. Beggs
Journal: Annals of Oncology (2024)
1099P COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma
Authors: P. Mohr, D. Debus, I. von Wasielewski, T. Tüting, C. Gebhardt, M.V. Heppt, J.C. Hassel, F. Ziller, M. Weichenthal, M. Aoun, G. Schley, J. Ulrich, J. Utikal, F. Meier, P. Terheyden, R. Gutzmer, D. Schadendorf
Journal: Annals of Oncology (2024)
1104P Early time-point 18F-FDG-PET/CT at week four (W4) as a prognostic biomarker of survival in metastatic melanoma (mM) patients (pts) on immunotherapy
Authors: N. Hribernik, K. Strasek, A. Studen, K. Zevnik, K. Škalič, R. Jeraj, M. Rebersek
Journal: Annals of Oncology (2024)
786P Exploring risk factors for recurrence in stage I uterine leiomyosarcomas: Is there a subgroup with a favorable prognosis?
Authors: A. Gallego, N. Martin-Calvo, M.M. Meydanli, D. Kaidarova, F. Borella, A. Ayhan, M. Sanchez-Salcedo, G. Khatib, M. Sanci, A.M. Perrone, C. Bessa P. Chaves, J. Mishra, A. Gil-Moreno, E. Cabezas, B. Martín, V. Theodoulidis, A. Berasaluce, A. González-Martín, L. Chiva
Journal: Annals of Oncology (2024)
1126P A phase II study of nivolumab/relatlimab in metastatic uveal melanoma
Authors: J. Lutzky, L. Hernandez-Aya, L. Feun, Z. Correa, J. King, C. Estevez, C. Decatur, J.J. Dollar, I. Reis, J.W. Harbour
Journal: Annals of Oncology (2024)
803MO CAR T cells reside in the bone marrow and inhibits healthy hematopoiesis
Authors: M. Ben Khelil, J. Srikanthan, R. Jelin, A. Arbab, L. Marcos-Kovandzic, R. Amine-Hneineh, A. Pages, V. Verge, M. Aglave, J. Baptiste Micol, M. Sabourin-Cousin, C. Quivoron, C. Marzac, L. Zitvogel, C. Castilla-Llorente, C. Bigenwald
Journal: Annals of Oncology (2024)
1226P Predictive value of circulating tumor DNA (ctDNA) before and shortly after curative treatment in early stage non-small cell lung cancer (NSCLC), and exploration of (pre-)analytical factors
Authors: M. van den Heuvel, C.G. Smith, M. Schuurbiers, K. Hartemink, R. Rintoul, K. Monkhorst, D. Van Den Broek, N. Rosenfeld
Journal: Annals of Oncology (2024)
1107P Characteristics and quality of life of nine-year survivors from 312 patients with metastatic melanoma treated with pembrolizumab
Authors: J.C. Hassel, A. Forschner, M. Erdmann, R. Gutzmer, K.C. Kähler, I. Holst, H. Stege, C. Franklin, A. Sindrilaru, L. Zimmer, L. Heinzerling, J. Utikal, F. Meier, C. Berking, C. Garbe, M. Weichenthal, D. Schadendorf, A. Hauschild, P. Mohr
Journal: Annals of Oncology (2024)
864P Clinical/biomarker data for neoadjuvant tislelizumab (TIS) plus chemotherapy (Chemo) in resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A single-arm, phase II trial
Authors: Q. Li, L. Cai, D. Kuang, C. Pan, J. Zhao, P. Huang, C. He, K. Xu, D. Liu, G. Long, Z. Liu, G. Hu, X. Lu
Journal: Annals of Oncology (2024)
1168P Overall survival (OS) and progression-free survival (PFS) in patients with advanced, non-resectable, progressive rectal NET treated with 90Y DOTA-TATE, 177Lu DOTA-TATE and mix of both as systemic radioligand therapy: Real-world data
Authors: J.B. Cwikla, A.D. Kolasińska-Ćwikła, A. Sankowski, J. Pałucki, K. Roszkowska-Purska, E. Chrapowicki, T. Ostrowski
Journal: Annals of Oncology (2024)
862P Neoadjuvant chemo-immunotherapy using carboplatin, nab-paclitaxel, oral metronomic therapy and low dose nivolumab for “borderline resectable” oral cavity carcinoma: A prospective phase II single-arm trial (NeoLOCUS)
Authors: P.K. Marimuthu, A.J. Tirkey, S. Sahu, A.O. John, J.T. Georgy, D.B. Thumaty, J. Riju, V. Konduru, M. Agrawal, B.K. Sasidharan, M. Mathew, S.K. Sidhique, A. Joel, R.T. Chacko, P. Jambunathan, K. Harikrishna, M. Thomas, J. Rani, A. Singh
Journal: Annals of Oncology (2024)
1115P Multiomics clustering of patients with cutaneous melanoma to reveal survival trends based on tumor immune evasion features
Authors: A. Leleytner, N. Lukashevich, E. Ocheredko, S. Ambaryan, M. Savchenko, A. Nadiryan, S.T. Yong, M. Goldberg, A. Bagaev, S. Kust
Journal: Annals of Oncology (2024)
1219P Integrating artificial intelligence (AI)-based lymphocytic infiltration assessment in early stage NSCLC: A sub-study of the TNM-I trial
Authors: F. Jabar, S. Andersen, E-E. Paulsen, M. Tafavvoghi, E. Richardsen, S.G.F. Wahl, R.H. Petersen, A-L.R. Bondgaard, P.B. Licht, M. Lund-Iversen, B.H. Gronberg, L. Fjellbirkeland, A. Helland, M. Pohl, D. Kwiatkowski, L-T.R. Busund, T. Donnem, M. Rakaee
Journal: Annals of Oncology (2024)
833P Latest results of GVM±R regimen for the salvage therapy of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Authors: W. Liu, W. Huang, Y. Xu, T. Wang, S. Yi, W. Sui, Y. Wang, Q. Wang, T. Yu, Y. Yan, S. Zhang, D. Zou, L. Qiu
Journal: Annals of Oncology (2024)
1200P Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Authors: M. Homs Soler, J. Kren, M.M. Bonsanto, K.C. Honselmann, T. Keck, F. Hemptenmacher, M. Banys- Paluchowski, A. Rody, M. Roesch, A.S. Merseburger, M.L. Ha-Wissel, E. Gaffal, J. Hundt, C. Rose, J.E. Neumann, N. Berg, C. Kümpers, V-W. Sailer, M. Oberländer, R. Brinkmann
Journal: Annals of Oncology (2024)
1228P Association between air pollution and frequency of driver mutation among a Hispanic population with lung cancer
Authors: M. Tamayo, A.F. Bejarano Ramirez, A.M. Baldion, S. Cruz Romero, S. Galeano Rodriguez, O. Valencia Estupiñan, L.G. Garcia-Herreros Hellal, A.F. Bernal-Tellez, M.P. Molina, M.J. Garcia, M. Valenzuela, J. Pardo, S. Dueñas-Hernandez, D.A. Uscategui-Lopez, T. Romero-Rivero, F. Serrano-Mugica, J.J. Ibarra-Nuñez, L. Pino, A.F. Cardona Zorrilla, B. Wills
Journal: Annals of Oncology (2024)
1074TiP A phase I study of GIGA-564, a minimally blocking anti-CTLA-4 monoclonal antibody
Authors: J.L. Gulley, K. Stadtmiller, M. Asensio, L. Cordes, E. Redmond, J. marte, R. Leong, D.M. Bracken-Clarke, E. Xue, O. Titova, E. Garmey, C. Millward, K. Hanna, E. Stone, J.M. Redman
Journal: Annals of Oncology (2024)
1045P The association of human leukocyte antigen variants in immune-related toxicity and efficacy in Chinese lung cancer patients treated with immune checkpoint inhibitors
Authors: Y. Zhang, H. Yan, Z. Liang, G. Zhou, Y. Wu, H. Qin, N. Yang, Z. Huang, D. Yang, Y. Zhang, K. Graham-Siegenthaler, R. Walls, S. Hamzic, Y. He, R. Mohindra, Z. Li, R. Luo, A. Saha, C. Hammer, G.S. Chandler
Journal: Annals of Oncology (2024)
975P Lenvatinib plus drug-eluting bead transarterial chemoembolization with or without hepatic arterial infusion chemotherapy for hepatocellular carcinoma (&gt; 7 cm) with portal vein tumor thrombosis: A retrospective multicenter cohort study
Authors: M. Cai, L. Liang, H. Chen, J. Zhang, N. Chen, W. Huang, Y. Guo, L. Lin, Y. Liu, C. Dan, X. Liu, J. Zhou, Y. Chen, K. Zhu
Journal: Annals of Oncology (2024)
1110P Follow-up brain imaging in patients with melanoma brain metastasis and immune checkpoint inhibitors
Authors: I. Ozdamar, S.H.A.E. Derks, L.S. Ho, E.L. van der Meer, K.A.T. Naipal, A. Joosse, M.J.A. de Jonge, M. Smits, M.J. van den Bent, J.L.M. Jongen, A.A.M. Van der Veldt
Journal: Annals of Oncology (2024)
1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma
Authors: P.A. Ascierto, J. Rodon, F.Y.F.L. De Vos, V. Gambardella, M. De Miguel, I. Marquez-Rodas, M. Gil Martín, C. Robert, M. Del Vecchio, V. Moreno Garcia, D. Schadendorf, R. Jamal, S. Sloan, M. Mclaughlin, S. Murray, B. Gomez-Carrillo Ruiz, E. Hsiue, S. Moody, A.M. Arance
Journal: Annals of Oncology (2024)
973P Atezolizumab plus bevacizumab or lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma: Overall survival using real-world data from TrinetX platform
Authors: L. Ugidos de la Varga, G. Hernández-Ibarburu, A. Parralejo Jimenez, J.D. Rodriguez-Castaño, J.J. Serrano, A. Ayuso, J. Rodriguez Pascual
Journal: Annals of Oncology (2024)
968P HAIC combined with lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors for advanced HCC with portal vein tumor thrombosis: A prospective controlled trial
Authors: X. Wang, K. Zheng, G. Cao, L. Xu, S. Fu, Y. Dai, P. Liu, S. Gao, S. Liu, F. Kou, Q. Gao, K. Wang, X. Yan, D. Xu, Q. Bao, L. Wang, J. Wu, C. Hao, X. Zhu, B. Xing
Journal: Annals of Oncology (2024)
1032P Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activity
Authors: P. Innamarato, N.J. Gilbert, A. de Mingo Pulido, M. Alkhouli, J. Fang, G. Sapena, S. Hall, H. Yin, Y. Zhang
Journal: Annals of Oncology (2024)
1103P Real-world efficacy of relatlimab and nivolumab in advanced or resectable melanoma
Authors: L. Karapetyan, S. Aflatooni, K. Ward, B. Withycombe, D. Kalos, Q. Mo, Z. Eroglu, A.S. Brohl, J. Markowitz, A. Tarhini, J. Messina, K.Y. Tsai, M. Perez, J.S. Zager, A. Sarnaik, R.I. Neves, V. Sondak, N.I. Khushalani
Journal: Annals of Oncology (2024)
1090P High concurrent interferon gamma signature expression in the primary tumor and lymph node metastasis is associated with superior outcome upon neoadjuvant ipilimumab + nivolumab in stage III melanoma
Authors: L. Hoeijmakers, P. Dimitriadis, S. Cornelissen, I. Reijers, B. van de Wiel, R.A. Scolyer, R.P.M. Saw, A.J. Spillane, A. Broeks, M. Lopez-Yurda, L. Grijpink-Ongering, G. Hospers, A.M. Menzies, A.C.J. van Akkooi, W. Van Houdt, G.V. Long, C.U. Blank
Journal: Annals of Oncology (2024)
1062P Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy
Authors: È. Sais, A. Plujà, C. Montanes, E. Bujons, F.J. Pineda, A. Iguaran, À. Roselló, A. Hernandez Martinez, E. Teixidor Vilà, A. Romera, J. Bosch-Barrera, A. Eraso, E. Oliva-Poch
Journal: Annals of Oncology (2024)
1085P Adoptive cell therapy with TCR gene-engineered T cells directed against MAGE-C2-positive melanoma: An ongoing phase I trial
Authors: B. van Dijk, C. Lamers, K. de Joode, M. de Beijer, C. Berrevoets, M. van Brakel, J. Tsui, K. Bezemer, S. de Wilde, M.J.A. de Jonge, S. Sleijfer, A.A.M. Van der Veldt, R. Debets
Journal: Annals of Oncology (2024)
1058P Hyperprogressive disease during immune checkpoint inhibitor: A cloudy phenomenon with real consequences
Authors: D. Bruyat, N. Girard, N. Penel, P-E. Heudel, A. Gonçalves, A-C. Madroszyk Flandin, G. Gravis, B. Chanez, B. Collineau, A-S. Chrétien, M. Beaufils, E. Billon, P. Rochigneux
Journal: Annals of Oncology (2024)
1059P Association between tumor longevity and immune-checkpoint inhibitor outcomes: A retrospective study in head and neck, lung, renal/urothelial cancers
Authors: R. Romanò, C. Airoldi, S. Alfieri, R. Miceli, S. Buriolla, S. Rota, F. Manoni, N. Crippa, C. Silvestri, S. Oldani, A. Sartore Bianchi, S. Siena, L.F.L. Licitra
Journal: Annals of Oncology (2024)
1029P Preclinical development of TCR-modified T cell therapies against mutated KRAS
Authors: H. Salter, L. Pase, A. Brass, Z. Bashir, D. Casarrubea, S. Virding Cullerton, J. Dunst, S. Horta, M. Masia-Balague, J. Lange, T. Parrot, A. Totomi, H. Uchtenhagen, S. Wang, R. Hill, R. Jarvis
Journal: Annals of Oncology (2024)
989O Novel gene therapy in advanced solid malignancies: A phase I/II clinical trial
Authors: L. Hahn, S. Irenaeus, J. Wenthe, E. Eriksson, A. Schiza, H. Dahlstrand, U. Olsson-Strömberg, J. Krause, A. Sundin, L.C. Sandin, J. Leja Jarblad, M. Liljefors, A. Loskog, G.J. Ullenhag
Journal: Annals of Oncology (2024)
1003P A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Authors: M. Beaufils, A. Mailliez, P. Sfumato, C. Vicier, M. Provansal Gross, M. Guerin, B. Chanez, N. Kotecki, A. Widemann, S. Panzolato, A. Boyer Chammard, P. André, C.L. Paturel, C. Gouarne, A.H. Awada, J.M. Boher, A. Gonçalves
Journal: Annals of Oncology (2024)
1037P Activating strong anti-tumor immunity with PTPN2/PTPN1 inhibitor: AC484
Authors: H. Ebrahimi-Nik, C.K. Baumgartner, A. Iracheta-Vellve, K.M. Hamel, K.E. Olander, T.G.R. Davis, K.A. McGuire, G. Halvorsen, O. Avila, C.H. Patel, M. Paddock, E. Farney, M. Matulenko, C. Beauregard, J.M. Frost, K. Yates, P.R. Kym, R.T. Manguso
Journal: Annals of Oncology (2024)
1101P Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study)
Authors: M. Mandalà, A. Ferrari, I. Brecht, K. Suijkerbuijk, L. Maschke, D. Giannarelli, A. Indini, M. Ubaldi, V.G. Atkinson, H. Helgadottir, S. Chiaravalli, M.D. De Pasquale, N. Benannoune, C. Robert, H.M. Kosela Paterczyk, S. Puig Sarda, D. Massi, G.V. Long, P.A. Ascierto, A.M.M. Eggermont
Journal: Annals of Oncology (2024)
1043P Advancing a multi-dimension KRAS mutation-specific T cell receptor (TCR) library with a 3S TCR targeting the G12D mutation to address large global patient populations
Authors: K. Crame, D. Alterauge, A-W. Mohr, J. Bittmann, D. Brechtefeld, M. Catarinella, K. Davari, M. Bürdek, P. Prinz, A. Coluccio, D.J. Schendel, G. Longinotti
Journal: Annals of Oncology (2024)
1262P Combined molecular analysis of circulating tumour DNA and tumour tissue to identify osimertinib resistance
Authors: T. van der Wel, M. Jebbink, S. Badrising, L. Steinbusch, G. Ruiter, W.S.M.E. Theelen, B.V. Veggel, J. Smit, S. Hashemi, A.J. Van Der Wekken, L.E. Hendriks, M.S. Paats, S. Ernst, D. Van Den Broek, L.J.W. Bosch, K. Monkhorst, E.F. Smit, M.C. Boelens, A.J. De Langen
Journal: Annals of Oncology (2024)
916P Deep spatial profiling of head and neck squamous cell carcinoma offers insights into the tumor microenvironment of hpv-stratified patients
Authors: A. Aggarwal, H. Zong, P. Bimbaum, B. Arbiv, Y. Shachaf, S. Bookstein, R. Elran, A. Laniado, G. Golan, K. Bloom, L.J. Diehl, E. Markovits
Journal: Annals of Oncology (2024)
940TiP INTerpath-007: A phase II/III, adaptive, randomized study of neoadjuvant and adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) for treatment of resectable locally advanced (LA) cutaneous squamous cell carcinoma (cSCC)
Authors: R. Ladwa, D. Davar, J. Lee, A.W. Silk, A. Popovtzer, N. Asher, M.A. Khattak, R. Meehan, T. Posadas, A. Wang, J. Yuan, N. Gross, S. Koyfman, D. Schadendorf
Journal: Annals of Oncology (2024)
925P External validation of the CD8 radiomics signature as a prognostic marker in recurrent or metastatic head and neck cancer treated with nivolumab
Authors: L. Adrien, C. Even, J.B. Hano, N. Deny, D. Mitrea, Y. Tao, G. Lefebvre, A. Daste, E.B. Saada, J. Fayette, P. Blanchard, V. Cifliku, F. Talebi, L. Monard, M. Texier, C. Robert, M. Classe, A. Auperin, E. Deutsch, R. Sun
Journal: Annals of Oncology (2024)
938TiP Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Authors: A. Psyrri, M. Moutafi, P. Economopoulou, I. Kotsantis, A. Kyriazoglou, E. Fountzilas, G. Fountzilas
Journal: Annals of Oncology (2024)
1246P PIT-3: A multicenter phase II trial of erlotinib induction followed by surgery in stage IIIA (N2) EGFR mutated non-small cell lung cancer
Authors: K. Takamochi, K. Suzuki, M. Tsuboi, S. Niho, S. Oyamada, T. Yamaguchi, F. Tanaka, Y. Maniwa, S. Shiono, H. Ito, T. Haruki, H. Suzuki, N. Ikeda, H. Watanabe, M. Okada
Journal: Annals of Oncology (2024)
885P Different patterns of treatment failure between p16+ and p16- patients affected by oropharyngeal carcinoma (OPC) undergoing (chemo)radiation
Authors: R. Gili, P. Bossi, L. Lalli, L.F.L. Licitra, M. Maddalo, J. Cacicedo Fernandez de Bobadilla, N. facchinetti, A. Garcia Castano, R. Mesia Nin, P. Bonomo, G. Sanguineti, P. Franco, A. Argiris, A. Psyrri, E. Orlandi
Journal: Annals of Oncology (2024)